Table 3 Pharmacologic strategies
Groups | Same AD1 | AD change2 | Combination3 | Dose increase4 |
|---|---|---|---|---|
Number of patients, % | N = 451 (26.7%) | N = 417 (43.2%) | N = 53 (15.5%) | N = 44 (14.6%) |
Time to change, months | Â | Â | Â | Â |
Mean | --- | 6.5 (3.9) | 5.4 (1.9) | 6.1 (3.5) |
Median | --- | 5.7 | 4.0 | 5.2 |
Mean age, years | 61.9 (15.1) | 60.8 (15.0)‡ | 61.1 (15.4) | 52.9 (11.4), |
Gender, female | 75.4% | 77.2% | 83.1% | 79.5% |
Comorbidity | Â | Â | Â | Â |
Mean number of episodes | 5.1 (3.4) | 5.5 (3.4) | 5.8 (3.9) | 5.1 (3.6) |
Mean RUBs | 2.7 (0.9) | 2.7 (0.9) | 2.8 (1.0) | 2.5 (1.0) |
Mean Charlson index | 0.4 (0.7) | 0.5 (0.7) | 0.4 (0.6) | 0.3 (0.7) |
Duration of MDD, years | 4.1 (3.7) | 5.2 (3.5)‡ | 6.4 (5.2) | 5.1 (3.5) |
Incident cases (N = 222) | 29.2%, | 18.2% | 9.8% | 20.4%‡ |
Prevalent cases (N = 743) | 70.1% | 81.5%‡ | 90.1%, | 79.5% |
Treatment compliance | 62.3%, | 67.1% | 64.8% | 69.2%, |
Treatment persistence | 30.5%, | 33.1% | 34.8% | 43.2%, |
Referrals to psychiatry (N = 199) |  |  |  |  |
Referral rate | 17.1%‡ | 23.5% | 28.2%‡ | 20.5% |
Mean referrals per patient | 0.2 (0.4) | 0.2 (0.5) | 0.3 (0.5)‡ | 0.2 (0.5) |
Time to referral, months | 6.3 (4.1) | 6.8 (4.0) | 4.4 (3.3) | 6.2 (3.8) |
Reasons for referral | Â | Â | Â | Â |
Disease severity (N = 82) | 39.0% | 39.8% | 53.3%‡ | 55.6%, |
No response to treatment (N = 107) | 59.7%, | 53.1%‡ | 33.3% | 44.4% |
Patient decision (N = 10) | 1.3% | 7.1% | 13.3% | 0.8% |
Cost model (euro) | Â | Â | Â | Â |
Healthcare costs | 782.1 | 901.4 | 1,041.8 | 984.9 |
Non-healthcare costs (productivity) | 1,392.4 | 1,710.6 | 1,631.3 | 1,978.1 |
Total costs | 2,174.4 | 2,612.0 | 2,673.1 | 2,963.1 |